ERBB2 and breast carcinoma: The Food and Drug Administration (FDA) approval of trastuzumab in 1998 represented a pivotal advancement in HER2-positive breast cancer treatment 7, 8, resulting in expanded therapeutic options and improved prognosis 9-11.